Mol Biochem Parasitol 2002, 122:211–216.CrossRefPubMed 64. Lancaster AK, Single RM, Solberg OD, Nelson MP, Thomson G: PyPop update–a software pipeline

for large-scale multilocus population genomics. Tissue Antigens 2007,69(Suppl 1):192–197.CrossRefPubMed 65. Rozas J, Sanchez-DelBarrio JC, Messeguer X, Rozas R: DnaSP, DNA polymorphism analyses by the coalescent and other methods. Bioinformatics 2003, 19:2496–2497.CrossRefPubMed 66. Rogier C, Ly AB, Tall A, Cisse B, Trape JF:Plasmodium falciparum clinical malaria in Dielmo, a holoendemic area in Senegal: no influence of acquired immunity on initial symptomatology and severity of malaria attacks. Am J Trop Med Hyg 1999, 60:410–420.PubMed 67. Rogier C, Commenges D,

Trape JF: Evidence for an age-dependent pyrogenic threshold of Plasmodium falciparum parasitemia VEGFR inhibitor in highly endemic populations. Am J Trop Med Hyg 1996, 54:613–619.PubMed 68. Sokhna CS, Rogier C, Dieye A, Trape JF: Host factors affecting the delay of reappearance of Plasmodium falciparum after radical selleck inhibitor treatment among a semi-immune population exposed to intense perennial transmission. Am J Trop Med Hyg 2000, 62:266–270.PubMed Authors’ contributions OMP designed the study. NN and JP established the experimental conditions for Pfmsp1 block2 amplification and sequencing. NN carried out sequencing with the help PI3K inhibitor of MTE and CB. OMP and NN conducted the genotyping analysis, database mining and curation/analysis. HJ carried out the serological assessment. AT, LM CS, JFT and CR conducted the epidemiological and clinical work and the sample collection. OMP, NN, HJ and CR analysed the data. FP and JO analysed the population structure and diversity, CR conducted the statistical analysis. Bay 11-7085 OMP wrote the manuscript with input from NN, FP, HJ and CR. All authors read and approved the final manuscript.”
“Background Chlamydophila pneumoniae is an important human respiratory pathogen that causes laryngitis, pharyngitis, bronchitis and community acquired pneumonia [1] and has been associated

with exacerbation of asthma [2, 3], atherosclerosis [4–6], arthritis [2, 7], Alzheimer’s disease [8, 9] and Multiple Sclerosis [10–13]. The ability of C. pneumoniae to remain viable within lung macrophages [14–16] provides a mechanism for dissemination of Chlamydia to other anatomical sites that may include the arterial wall [17] and the brain. Rapid and successful treatment of C. pneumoniae respiratory infections is therefore important to ensure complete clearance of the bacteria in order to avoid infections elsewhere in the body. Antibiotics such as azithromycin, clarithromycin, erythromycin, and doxycycline have been used to treat C. pneumoniae respiratory infections [18]. However, clinical isolates of Chlamydia resistant to azithromycin and erythromycin have been reported [19], and some chlamydial species including C. pneumoniae develop resistance to antibiotics in vitro [20–25].